J&J Seeks To Reclaim Schering's Arthritis Drug Rights

Law360, New York (May 28, 2009, 12:00 AM EDT) -- Johnson & Johnson has filed a demand for arbitration to sever an agreement between a subsidiary and Schering-Plough Corp. over the full rights to market and sell arthritis treatments Remicade and Simponi given the pending merger between Schering-Plough and Merck & Co.

In the demand filed Wednesday with the American Arbitration Association, Johnson & Johnson requested a ruling that the merger constitutes a change of control that permits the termination of the agreements between Schering-Plough and Johnson & Johnson subsidiary Centocor Ortho Biotech Inc.

The drug...
To view the full article, register now.